%0 Journal Article
%@ 1532-1827
%A Dixon, SC
%A Nagle, CM
%A Wentzensen, N
%A Trabert, B
%A Beeghly-Fadiel, A
%A Schildkraut, JM
%A Moysich, KB
%A deFazio, A
%A Risch, HA
%A Rossing, MA
%A Doherty, JA
%A Wicklund, KG
%A Goodman, MT
%A Modugno, F
%A Ness, RB
%A Edwards, RP
%A Jensen, A
%A Kjaer, SK
%A Hogdall, E
%A Berchuck, A
%A Cramer, DW
%A Terry, KL
%A Poole, EM
%A Bandera, EV
%A Paddock, LE
%A Anton-Culver, H
%A Ziogas, A
%A Menon, U
%A Gayther, SA
%A Ramus, SJ
%A Gentry-Maharaj, A
%A Pearce, CL
%A Wu, AH
%A Pike, MC
%A Webb, PM
%D 2017
%F discovery:1552440
%I NATURE PUBLISHING GROUP
%J British Journal of Cancer
%K Science & Technology, Life Sciences & Biomedicine, Oncology, Ovarian Cancer, Aspirin, Nonsteroidal Anti-Inflammatory Drugs, NSAID, Paracetamol, Acetaminophen, Pooled Analysis, Survival, Nonsteroidal Antiinflammatory Drugs, Aspirin, Metaanalysis, Diagnosis
%N 9
%P 1223-1228
%T Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium
%U https://discovery.ucl.ac.uk/id/eprint/1552440/
%V 116
%X BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited.  Methods: Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among  7694 women with invasive epithelial ovarian cancer (4273 deaths).        RESULTS: Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95%  confidence intervals): aspirin 0.96 (0.88–1.04); non-aspirin NSAIDs 0.97 (0.89–1.05); acetaminophen 1.01 (0.93–1.10)), nor with  progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly  defining non-use as less than once per week (pHR ¼ 0.89 (0.82–0.98)).      CONCLUSIONS: Although this study did not show a clear association between analgesic use and ovarian cancer survival, further  investigation with clearer definitions of use and information about post-diagnosis use is warranted.
%Z © 2017 Cancer Research UK. All rights reserved